BioPharmSignal logoBioPharmSignal

Biotech News

Novan Announces Late-Breaking Abstract Accepted for Presentation at American Academy of Dermatology's (AAD) 2022 Annual Meeting

Novan (NOVN)NovanConference / presentation

DURHAM, N.C., March 24, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN), today announced that data from its pivotal Phase 3 study of berdazimer gel 10.3% (SB206) for the treatment of molluscum contagiosum was selected for an oral presentation at a late-breaker session at the American Academy of Dermatology's (AAD)...

Related news

NOVNNovan2022-10-14 08:30 EST

Novan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference®

NOVNNovan2022-12-01 09:00 EST

Novan to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference

View all latest news

Novan

Novan was a dermatology-focused biotechnology company built around nitric oxide-based therapies for skin conditions and related inflammatory indications. Its story was centered on a narrow clinical platform and the challenge of turning topical science into a durable commercial path.

Recent company news

NOVNNovan2023-07-17 08:45 EST

Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection

NOVNNovan2023-06-05 09:00 EST

Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders

NOVNNovan2023-05-31 16:05 EST

Novan Focuses Strategic Direction and Announces Restructuring

NOVNNovan2023-05-15 06:45 EST

Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update

NOVNNovan2023-05-08 09:05 EST

Novan to Report First Quarter 2023 Financial Results on May 15, 2023

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States